1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Longer-Term DME Data Bolster Optimism Around Mechanism For Unity’s UBX1325

 
• By Alaric DeArment

The company announced 48-week, Phase IIa data for the drug in diabetic macular edema, an update from 24-week data the company announced in November.

Unity announced Phase IIa follow-up data in diabetic macular edema for UBX1325 • Source: Shutterstock

UNITY Biotechnology, Inc. got further proof-of-concept results for the mechanism of action of UBX1325 as it unveiled data showing the drug is effective in diabetic macular edema (DME), despite earlier data showing the drug failed in wet age-related macular degeneration (AMD).

The company announced 48-week data on 24 April from the Phase IIa BEHOLD study in patients receiving a single dose of UBX1325 and for whom treatment with anti-VEGF drugs had failed. The data showed improvement on secondary endpoints like best-corrected visual acuity (BCVA), central subfield thickness (CST) and percentage of participants going without anti-VEGF rescue treatment among patients treated with UBX1325 versus those receiving sham treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.